Kourtney Houser, MD
Ophthalmology · Memphis, TNNPI 1700148053
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $78,866 of the $103,531 with a category attached, or 76.2%. 25 manufacturers reported payments, led by Alcon Research LLC at 28.4% of the total. 2025 is the largest year on record at $37,721, 7.3 times the $5,169 reported in 2019. Among ophthalmology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $612.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$29K
- Alcon$23K
- Bausch & Lomb Americas Inc.$16K
- Sight Sciences, Inc.$8K
- Carl Zeiss Meditec, Inc.$7K
- Rayner Intraocular Lenses Limited$6K
- plus $15K from 19 others
What the payments were for
- Consulting fees$78,86676%
- Speaking & faculty fees$15,03715%
- Travel & lodging$3,1133%
- Food & beverage$6,5156%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 14 | $29,392 |
| Alcon | 44 | $22,719 |
| Bausch & Lomb Americas Inc. | 12 | $15,844 |
| Sight Sciences, Inc. | 8 | $7,589 |
| Carl Zeiss Meditec, Inc. | 8 | $6,689 |
| Rayner Intraocular Lenses Limited | 4 | $6,253 |
| AbbVie(2 entities) | 8 | $4,585 |
| Dompe US, Inc. | 6 | $3,272 |
| Tearlab Corp | 2 | $1,400 |
| Eyevance Pharmaceuticals LLC | 3 | $1,323 |
| Sun Pharmaceutical Industries Inc. | 16 | $1,138 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $1,129 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $845 |
| Novartis | 13 | $351 |
| Kala Pharmaceuticals, Inc. | 4 | $229 |
| Tarsus Pharmaceuticals, Inc. | 3 | $191 |
| Oyster Point Pharma, Inc. | 2 | $190 |
| Shire North American Group Inc | 2 | $152 |
| Quidel Corporation | 2 | $62 |
| Ocular Therapeutix, Inc. | 3 | $52 |
| Carl Zeiss Meditec USA, Inc. | 1 | $36 |
| Amgen | 2 | $32 |
| Biotissue Holdings Inc. | 1 | $23 |
| Vyera Pharmaceuticals, LLC | 1 | $23 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Unity$18,606
- AcrySof IQ PanOptix UV IOL$10,994
- VisuMax$6,300
- OMIDRIA$4,245
- TearCare SmartLid$4,125
- TEARCARE(TM) (2.2) SYSTEM KIT$4,125
- MIEBO$4,000
- VERACITY SURGICAL$3,900
- STELLARIS$3,500
- VUITY$3,379
- TEARCARE SYSTEM$3,375
- Oxervate$3,250
- QUATERA 700$2,925
- XIIDRA$2,795
- LOTEMAX SM$2,500
- VYZULTA$2,500
- enVista MX60 IOL$2,500
- MEL 90$2,400
- CIRRUS HD-OCT$2,400
- CALLISTO eye$2,400
How this compares
$103,531 in reported general payments places this provider in the 95th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 31 | $1,067,515 |
| RestasisCyclosporine | 107 | $92,616 |
| XiidraLifitegrast | 38 | $38,848 |
| TyrvayaVarenicline Tartrate | 22 | $15,276 |
| Prednisolone Acetate | 299 | $13,428 |
| Cyclosporine | 21 | $11,066 |
| MieboPerfluorohexyloctane/Pf | 11 | $9,767 |
| Loteprednol Etabonate | 42 | $4,734 |
| ValacyclovirValacyclovir Hcl | 32 | $2,147 |
| MoxifloxacinMoxifloxacin Hcl | 90 | $1,959 |
| Ketorolac Tromethamine | 41 | $972 |
| Doxycycline Monohydrate | 73 | $913 |
| Fluorometholone | 13 | $742 |
| Ofloxacin | 70 | $714 |
| Brimonidine Tartrate | 61 | $607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $3,272 | $1,067,51531 claims |
| AbbVieRestasis | $4,585 | $92,616107 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $15,844 | $48,61549 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $190 | $15,27622 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $1,129 | $4,73442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Memphis
- Melissa ToyosMemphis$1.3M
- Rolando ToyosMemphis$809K
- Brian FowlerMemphis$206K
- Brian JerkinsMemphis$150K
- James FreemanMemphis$141K
- John FreemanMemphis$136K
- Penny AsbellMemphis$131K
- Subba GollamudiMemphis$67K
- Andrew CrothersMemphis$13K
- Brian SmithMemphis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.